Expression and Prognostic Role of CXCR4/CXCL12/CXCR7 and mTOR Pathways in Neuroendocrine Tumors (NETs) Abstract #860

Introduction: The chemokine receptor CXCR4 interacts with the ligand CXCL12 to exert proliferative and chemotactic effects. CXCR4 activates mTOR through phosphorylation of its two effectors downstream:4EBP1and S6K
Aim(s): To evaluate expression and prognostic role of CXCR4-CXCL12-CXCR7, as well as mTOR pathways in a consecutive series of patients with endocrine tumors (NETs)
Materials and methods: 53 human NETs were included: 16 P-NET,19 GI-NET, and 18 MTC were analyzed for expression of CXCR4, CXCL12 and CXCR7 by qRT-PCR. Moreover, CXCR4, CXCL12 and CXCR7 and mTOR pathway was evaluated by immunohistochemistry (IHC) in the patient cohort
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Doctor Luisa Circelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)
Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: student Concetta Sciammarella
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella
#2786 Outcome of NET Liver Metastases Treated by TAE Using Microspheres
Introduction: Liver metastases are common in patients with neuroendocrine tumors (NETs), which are associated with the prognosis. Transarterial embolization (TAE) is one of the options for selective therapy in patients with multiple unresectable progressive liver metastases after chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Xiaoliang Chen
Authors: Chen X, Hu L, ...
#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study
Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD, Ph.D. Francesca Spada
#2711 Gastric Neuroendocrine Neoplasms: Clinical Management and Outcomes in a Cohort of 54 Patients
Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10-20% can be type 3 or type 4 Gastric NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Alexandra Victor
Authors: Victor A, Ramage J, Cope J, Maclean R, ...